In a move to strengthen its worldwide footprint, Pune-based Brinton Pharmaceuticals recently inaugurated its global Research and Development (R&D) centre in the United Kingdom (UK).

Unveiling the Global R&D Centre located at the Health Technical & Business Park, Runcorn, Cheshire, England, in the presence of Rahulkumar Darda, Chairman and Managing Director, Brinton Pharma, Minister of State at the Department for Business & Trade, UK,  Nigel Huddleston said, "By deepening our trading relationship, the UK-India trade deal can pave the way for even more investment opportunities and make it easier for UK and Indian companies such as Brinton Healthcare UK to do business in each other's countries."

"The investment relationship between UK and India already supports over half a million jobs across both economies and a forward-facing UK-India free trade agreement (FTA) can create new investment opportunities for British and Indian businesses. A strong trade deal can boost the economic links between the UK and India and is expected to boost the UK economy by billions over the longer term. Total trade in goods and services between the UK and India in 2022 amounted to £34 billion, in current prices", Nigel Huddleston added.

Brinton with a global presence spanning across 32 countries is seeing the R&D centre as a strategic facility that will deepen its ongoing research in the areas of health and life sciences and support the company's ambition to build next generation healthcare products.  

The R&D centre's primary focus is on innovations in topical skin delivery systems & focus on studying various skin disorders. Brinton has introduced 14 unique formulations, and the new R&D centre aims to develop affordable novel products using niche technologies.